Answers are grounded in this paper and cite their sources.
A randomized trial evaluates a Staphylococcus aureus vaccine's safety and efficacy in adults with recent skin infections, suggesting limited effectiveness.
Background A vaccine that prevents Staphylococcus aureus skin and soft tissue infections (SA-SSTIs) would have a major impact on public health. Methods A two-part randomized study began with a phase 1, first-in-human, dose-escalation that tested the safety of the five-antigen S. aureus vaccine (SA5Ag), half or full antigen doses, unadjuvanted or with AS01E adjuvant, in 32 healthy volunteers aged 18–50 years. In the phase 2, proof-of-principle part, 194 participants aged 18–64 years with recent SA-SSTI were administered two full doses of AS01E-adjuvanted SA5Ag (SA5Ag-Adj) or placebo, 2 months apart, and followed for 12 months. Vaccine safety (primary objective), vaccine efficacy (VE; secondary/tertiary objectives), and immunogenicity (tertiary objectives) were evaluated. Results Following a positive safety evaluation in phase 1, participants were enrolled into phase 2 until predefined futility criteria were met at the interim efficacy analysis. Twelve months post-dose 2, SA5Ag-Adj showed no efficacy in preventing recurrent SA-SSTIs (VE: -38.1% [95% confidence interval -245.8, 40.9]), despite inducing robust functional immune responses against three (CP5, CP8, Hla) of the five vaccine antigens. Solicited local adverse events (AEs) were more frequent in the SA5Ag-Adj versus placebo group but were mostly mild or moderate in intensity. Frequencies of medically-attended AEs and serious AEs were similar across groups. Conclusions In participants with recent history of SA-SSTI, SA5Ag-Adj vaccine had an acceptable safety profile, induced robust functional immune responses against CP5, CP8, and Hla antigens, but did not reduce the rate of recurrent SA-SSTIs at 12 months from last dose.
No takes yet. Share an insight, caveat, or question.
Athan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: